Login to Your Account



Biogen Idec, Knopp Launch Phase III Trial for ALS Drug

By Marie Powers


Friday, April 1, 2011
Development partners Biogen Idec and privately held Knopp Biosciences LLC have enrolled the first patient in EMPOWER, a multinational Phase III study evaluating the efficacy, safety and pharmacokinetics of the drug candidate dexpramipexole (KNS-760704) in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and motor neuron disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription